| Literature DB >> 34239117 |
Michael Super1,2, Edward J Doherty1, Mark J Cartwright1, Benjamin T Seiler1, Fernanda Langellotto1, Nikolaos Dimitrakakis1, Des A White1, Alexander G Stafford1, Mohan Karkada1, Amanda R Graveline1, Caitlin L Horgan1, Kayla R Lightbown1, Frank R Urena1, Chyenne D Yeager1, Sami A Rifai1, Maxence O Dellacherie3, Aileen W Li3, Collin Leese-Thompson1, Hamza Ijaz1, Amanda R Jiang2, Vasanth Chandrasekhar1, Justin M Scott1, Shanda L Lightbown1, Donald E Ingber1,2,3, David J Mooney4,5.
Abstract
Most bacterial vaccines work for a subset of bacterial strains or require the modification of the antigen or isolation of the pathogen before vaccine development. Here we report injectable biomaterial vaccines that trigger potent humoral and T-cell responses to bacterial antigens by recruiting, reprogramming and releasing dendritic cells. The vaccines are assembled from regulatorily approved products and consist of a scaffold with absorbed granulocyte-macrophage colony-stimulating factor and CpG-rich oligonucleotides incorporating superparamagnetic microbeads coated with the broad-spectrum opsonin Fc-mannose-binding lectin for the magnetic capture of pathogen-associated molecular patterns from inactivated bacterial-cell-wall lysates. The vaccines protect mice against skin infection with methicillin-resistant Staphylococcus aureus, mice and pigs against septic shock from a lethal Escherichia coli challenge and, when loaded with pathogen-associated molecular patterns isolated from infected animals, uninfected animals against a challenge with different E. coli serotypes. The strong immunogenicity and low incidence of adverse events, a modular manufacturing process, and the use of components compatible with current good manufacturing practice could make this vaccine technology suitable for responding to bacterial pandemics and biothreats.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34239117 DOI: 10.1038/s41551-021-00756-3
Source DB: PubMed Journal: Nat Biomed Eng ISSN: 2157-846X Impact factor: 25.671